Truist Financial Reaffirms Buy Rating for UnitedHealth Group (NYSE:UNH)

UnitedHealth Group (NYSE:UNH)‘s stock had its “buy” rating reiterated by Truist Financial in a report released on Wednesday, Benzinga reports. They currently have a $600.00 target price on the healthcare conglomerate’s stock. Truist Financial’s price objective indicates a potential upside of 24.93% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Erste Group Bank reiterated a “hold” rating on shares of UnitedHealth Group in a research note on Wednesday, March 13th. Oppenheimer restated an “outperform” rating and set a $610.00 target price on shares of UnitedHealth Group in a research report on Wednesday, January 17th. Morgan Stanley dropped their target price on UnitedHealth Group from $618.00 to $584.00 and set an “overweight” rating on the stock in a research report on Friday, April 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $596.00 price target on shares of UnitedHealth Group in a report on Thursday, February 29th. Finally, Piper Sandler decreased their price target on shares of UnitedHealth Group from $584.00 to $581.00 and set an “overweight” rating on the stock in a report on Wednesday, January 17th. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, UnitedHealth Group has a consensus rating of “Moderate Buy” and an average price target of $571.20.

UnitedHealth Group Stock Performance

Shares of NYSE UNH traded up $11.39 during midday trading on Wednesday, reaching $480.28. The company’s stock had a trading volume of 6,631,769 shares, compared to its average volume of 4,434,561. UnitedHealth Group has a 12-month low of $436.38 and a 12-month high of $554.70. The firm has a 50 day moving average price of $490.31 and a 200-day moving average price of $515.63. The stock has a market capitalization of $442.78 billion, a P/E ratio of 20.17, a PEG ratio of 1.22 and a beta of 0.54. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.79 and a quick ratio of 0.79.

UnitedHealth Group (NYSE:UNH) last announced its earnings results on Tuesday, April 16th. The healthcare conglomerate reported $6.91 earnings per share for the quarter, topping analysts’ consensus estimates of $6.54 by $0.37. UnitedHealth Group had a return on equity of 26.39% and a net margin of 6.02%. The firm had revenue of $99.80 billion for the quarter, compared to the consensus estimate of $99.23 billion. During the same quarter in the previous year, the business earned $6.26 EPS. The company’s revenue was up 8.6% compared to the same quarter last year. As a group, equities analysts predict that UnitedHealth Group will post 27.69 earnings per share for the current year.

Insiders Place Their Bets

In other UnitedHealth Group news, CAO Thomas E. Roos sold 858 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $525.79, for a total value of $451,127.82. Following the completion of the sale, the chief accounting officer now directly owns 32,289 shares in the company, valued at $16,977,233.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other UnitedHealth Group news, CAO Thomas E. Roos sold 858 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $525.79, for a total transaction of $451,127.82. Following the completion of the transaction, the chief accounting officer now owns 32,289 shares of the company’s stock, valued at $16,977,233.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Erin Mcsweeney sold 1,236 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $483.48, for a total transaction of $597,581.28. Following the transaction, the executive vice president now directly owns 9,364 shares of the company’s stock, valued at approximately $4,527,306.72. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On UnitedHealth Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. Richelieu Gestion SA bought a new stake in UnitedHealth Group in the 4th quarter worth approximately $26,000. Robbins Farley bought a new stake in UnitedHealth Group in the 3rd quarter worth approximately $25,000. CGC Financial Services LLC boosted its stake in shares of UnitedHealth Group by 1,000.0% during the 4th quarter. CGC Financial Services LLC now owns 55 shares of the healthcare conglomerate’s stock worth $29,000 after acquiring an additional 50 shares during the last quarter. True Wealth Design LLC purchased a new position in shares of UnitedHealth Group during the 4th quarter worth $31,000. Finally, NewSquare Capital LLC boosted its stake in shares of UnitedHealth Group by 340.0% during the 3rd quarter. NewSquare Capital LLC now owns 66 shares of the healthcare conglomerate’s stock worth $33,000 after acquiring an additional 51 shares during the last quarter. Institutional investors own 87.86% of the company’s stock.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.